Heymach J, et al. A phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC). IASLC 2018; abstract OA02.06.
Overleving Europese adolescenten en jongvolwassenen met kanker is verbeterd
apr 2024 | Leukemie, Neuro-oncologie